AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PHB1/PHB2 identified as blood-borne tumor antigens.
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- Differential immunization has identified PHB1/PHB2 as blood-borne tumor antigens.
"Early diagnosis of cancer is crucial for successful treatment. Noninvasive assays for detecting tumor-derived antigens in serum and other bodily fluids have the potential to screen healthy individuals for hitherto undetected cancers. Very few such assays have been successfully developed, in part because identifying potential target antigens remains a challenge. To identify new blood-borne tumor antigens for the purpose of establishing such assays, we have developed a novel technique called differential immunization," scientists in Germany report.
"Using this method, we have identified PHB1 and PHB2, proteins thought to function as mitochondrial chaperones and transcriptional regulators, as antigens released from colorectal tumors in vivo, said Jorg Mengwasser and collaborators at the Forschungszentrum Karlsruhe and Humboldt-University. "Serum from colorectal patients contains significantly higher levels of these antigens ...
- 'Commercializing on Tumor Antigens: Analytical Perspectives'; - New 'de-novo'...
- Press release article from: PR Newswire May 14, 2002 700+ words
...a new report, "Commercializing On Tumor Antigens: Analytical Perspectives", that...report we have identified more than 60 tumor antigens that are in line for commercialization...an updated summary of the field of tumor antigens today, for example discussing the...
- Research and Markets: Commercializing on Tumor Antigens: Analytical...
- Press release article from: Business Wire July 14, 2004 700+ words
DUBLIN, Ireland -- Tumor Antigens Industry, Worth an Estimated...addition of Commercializing on Tumor Antigens: Analytical Perspectives to...analyst at a VC firm. More than 60 tumor antigens have been identified that are...
- Transfection of tumor antigens generates cytotoxic T lymphocytes.
- Newspaper article from: Biotech Week August 4, 2004 700+ words
...amp; NewsRx.net) -- Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged...study in Molecular Therapy (Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged...
- Regulatory T cells may have a role in poor immune response against tumor...
- Newspaper article from: Vaccine Weekly November 27, 2002 700+ words
...ELS, senior medical writer - The weak immunogenicity of tumor antigens may be due to regulatory T cells that suppress the response...and may partly explain the poor immune response against tumor antigens." The corresponding author for this study is David C...
- Regulatory T cells may have a role in poor immune response against tumor...
- Newspaper article from: Cancer Weekly November 26, 2002 700+ words
...ELS, senior medical writer - The weak immunogenicity of tumor antigens may be due to regulatory T cells that suppress the response...and may partly explain the poor immune response against tumor antigens." The corresponding author for this study is David C...
- RNA-transfected cells induce responses against viral and tumor antigens.
- Newspaper article from: Health & Medicine Week May 3, 2004 700+ words
...necessity of HLA matching," stated Christina M. Coughlin and colleagues at the University of Pennsylvania. "For viral and tumor antigens, CD40-B/RNA technology induced cytotoxic T lymphocytes (CTLs) from adults and children, which could be identified...
- Method for identifying new tumor antigens developed.
- Newspaper article from: Genomics & Genetics Weekly April 4, 2003 700+ words
2003 APR 4 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced that it has added to its technology portfolio by expanding the license with the University of British Columbia in Vancouver, Canada. The added technology, developed under the Collaborative Research Agreement between
- Esdifan debuts.(CVS Corp. unveils tumor antigens)(Brief Article)
- Magazine article from: Chain Drug Review November 21, 2005 700+ words
CVS Corp. has begun carrying Esdifan, a natural remedy targeted to those who suffer from irritable bowel syndrome. The product, from ZEO Health Ltd., is also on store shelves at outlets operated by Happy Harry's Inc.
Source: HighBeam Research, PHB1/PHB2 identified as blood-borne tumor antigens.